Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gu-Ben-Fang-Xiao-Tang (GBFXT) is a traditional Chinese medicine (TCM) formula consisting of 11 medicinal plants, including *Radix Astragali* and *Ginseng radix*. It has been used for over 30 years at the Jiangsu Provincial Hospital of Traditional Chinese Medicine in Nanjing, China, primarily for the treatment of bronchial asthma during the remission stage. The formula is derived from the classical TCM prescription Yu-Ping-Feng-San. GBFXT works through a multi-targeted mechanism that includes modulating the Th17/Treg immune balance to attenuate airway inflammation, suppressing endoplasmic reticulum (ER) stress responses by targeting proteins such as ORMDL3, BiP, and CHOP, and regulating lipid metabolism via activation of the AMPK pathway. Clinical and preclinical studies have demonstrated its ability to reduce airway hyperresponsiveness and decrease inflammatory cell infiltration in the lungs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gu-Ben-Fang-Xiao-Tang.